Alpha-Blockade in the Treatment of Symptomatic Benign Prostatic Hyperplasia

Eri, Lars M.; Tveter, Kjell J.

doi:10.1097/00005392-199509000-00003

Cited by 34 publications

(59 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1 Medical therapy, and particularly alpha-blockade therapy, has been extensively studied in double-blind placebo-controlled studies by urologists on outpatients, and usually in hospital setting. 2 Those ef®cacy studies have consistently demonstrated the ef®cacy and safety of alpha 1 -blocker in the treatment of BPH. 3 In particular alfuzosin has been proven to have a good bene®t/risk ratio.…”

Section: Introductionmentioning

confidence: 99%

Three-year prospective study of 3228 clinical BPH patients treated with alfuzosin in General Practice

Lukacs

Grange

Comet

et al. 1998

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

Objectives: To investigate (a) the magnitude and durability of symptom score reduction and HRQL score improvement (including sexual drive); (b) adverse outcomes; and (c) progression to acute urinary retention and prostate surgery up to three years of treatment with alfuzosin.Methods: Three thousand two hundred and twenty-eight BPH-patients out of 812 centers were included in a prospective three-year open-labelled study and treated with alfuzosin (immediate release formulation) at the recommended dosage. A symptom score (Boyarsky modi®ed) and a 20-item BPH speci®c HRQL score including three questions of sexuality (Urolife TM BPH QoL 20) were selfadministered at baseline, 3,6,12,18,24,30, and 36 months.Results: Two thousand ®ve hundred and seventy-nine patients (79.9%) completed the study at the end of three years. Symptom score was signi®cantly reduced by 54% at 3 months and this reduction was maintained up to 36 months (748.4%); HRQL score was signi®cantly improved by 45.4% at 12 months and this improvement was maintained up to 36 months ( 43.4%). Alfuzosin was well tolerated: the quantitative and qualitative distribution of adverse events was similar to that previously observed in placebo-controlled studies (vertigo/dizziness: 2.1%). Adverse events accounted for 4.2% of the drop-outs. 120 patients (3.7%) were operated on for BPH and nine patients (0.3%) experienced acute urinary retention.Conclusion: This medical outcomes study con®rms the long-term safety pro®le of alfuzosin in the naturalistic conditions of general practice and highlights the need to measure HRQL in the context of patient's preferences.

show abstract

Section: Introductionmentioning

confidence: 99%

Three-year prospective study of 3228 clinical BPH patients treated with alfuzosin in General Practice

Lukacs

Grange

Comet

et al. 1998

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

show abstract

“…However, as concern has been expressed over the development of tolerance to alpha-1 adrenoceptor antagtom scores (41-58% vs 12-36%) and total symptom scores (32-44% vs 11-30%). Terazosin was not signifionists [31], further controlled studies of long-term treatment are needed. cantly diÂerent from placebo in its eÂect on residual volume.…”

Section: Alpha Adrenoceptor Antagonists Past and Presentmentioning

confidence: 97%

“…Eri and Tveter [31] have reviewed published results from 29 use in BPH should be very selective for prostatic alpha-1 receptors and produce little or no side-eÂects related to randomized, placebo-controlled trials of alpha-1 selective adrenoceptor antagonists. A total of 3464 patients were systemic or vascular alpha blockade.…”

Section: Alpha Adrenoceptor Antagonists Past and Presentmentioning

confidence: 99%

Alpha adrenoceptor blockade in the treatment of benign prostatic hyperplasia: past, present and future

Kirby

Pool

1997

British Journal of Urology

View full text Add to dashboard Cite

“…A variety of a 1 blockers are available and their use generally results in a 6 -31% improvement in symptom score within the first 2 -3 weeks. 30,31 Maximum urinary flow rate can also be increased by up to 3.9 ml/s. 30 In terms of sexual function, the effect of the different a 1 blockers on ejaculation is shown in Table 2.…”

Section: Medical Therapymentioning

confidence: 99%

“…30,31 Maximum urinary flow rate can also be increased by up to 3.9 ml/s. 30 In terms of sexual function, the effect of the different a 1 blockers on ejaculation is shown in Table 2. 26,31 -37 The European Tamsulosin Group reported that at 3 y follow-up, 2.9% of patients had ED and 4.3% ejaculation disorders.…”

Section: Medical Therapymentioning

confidence: 99%

Impact of treatment of BPH on sexuality

Schulman

2001

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

Benign prostatic hyperplasia (BPH) can have a profound affect on a patient's quality of life and sexual function and is considered by patients to be one of the most important aspects affected by the disease. Different treatments can produce a variable response in terms of the patient's quality of life, including sexual activity and satisfaction. Varying rates of erectile dysfunction (ED) and retrograde ejaculation following surgery for BPH have been reported. In general, the incidence of these side-effects is less after minimally invasive therapies, such as interstitial laser coagulation and transurethral microwave therapy, but the data available are limited. The lowest rates of sexual dysfunction are reported with medical therapies. The 5a-reductase inhibitor, finasteride, can result in ED in 5 -9% of patients and ejaculation disorders in 0.8 -2.0%. With the exception of tamsulosin, a 1 blockers are associated with a low rate of sexual dysfunction. No cases of ED have been reported with alfuzosin and abnormal ejaculation with terazosin or alfuzosin is negligible. Indeed, early research suggests a beneficial effect of a 1 blockers on sexual function. In addition to information on the efficacy of a particular therapy, patients should be informed of side effects, in particular those relating to sexual function, in order that they can make informed treatment decisions. Prostate Cancer and Prostatic Diseases (2001) 4, Suppl 1, S12-S16.

show abstract

Alpha-Blockade in the Treatment of Symptomatic Benign Prostatic Hyperplasia

Cited by 34 publications

References 0 publications

Three-year prospective study of 3228 clinical BPH patients treated with alfuzosin in General Practice

Three-year prospective study of 3228 clinical BPH patients treated with alfuzosin in General Practice

Alpha adrenoceptor blockade in the treatment of benign prostatic hyperplasia: past, present and future

Impact of treatment of BPH on sexuality

Contact Info

Product

Resources

About